Showing 1 - 7 results of 7 for search 'Lourdes Rodriguez-Fernandez-Freire', query time: 0.03s Refine Results
  1. 1
    Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)

    Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain) by Ricardo Ruiz-Villaverde, Lourdes Rodriguez Fernandez-Freire, Pilar Font-Ugalde, Manuel Galan-Gutierrez

    Published 2022-08-01
    Get full text
    Article
  2. 2
    Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines

    Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic G... by Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Amalia Pérez-Gil, Pilar Font-Ugalde, Manuel Galán-Gutiérrez

    Published 2022-11-01
    Get full text
    Article
  3. 3
    Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review

    Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review by Lluís Puig, Lourdes Rodríguez Fernández-Freire, Ramón Burgos-Pol, Ismael Gomez, Carmen Peral, Susana Gomez, Francisco José Rebollo Laserna

    Published 2019-05-01
    Get full text
    Article
  4. 4
    Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives

    Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives by Ricardo Ruiz-Villaverde, Fiorella Vasquez-Chinchay, Lourdes Rodriguez-Fernandez-Freire, Jose C. Armario-Hita, Amalia Pérez-Gil, Manuel Galán-Gutiérrez

    Published 2022-09-01
    Get full text
    Article
  5. 5
    Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study [version 2; peer review: 2 approved]

    Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study [version 2; peer review: 2 approved] by Fiorella Vasquez Chinchay, Manuel Galán-Gutiérrez, Jose C. Armario-Hita, Amalia Pérez-Gil, Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire

    Published 2022-11-01
    Get full text
    Article
  6. 6
    Bimekizumab: Short-Term Effectiveness and Safety in Real Clinical Practice in Andalucia, Spain

    Bimekizumab: Short-Term Effectiveness and Safety in Real Clinical Practice in Andalucia, Spain by Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Marta Cebolla-Verdugo, Alvaro Prados-Carmona, Carlos Hernández-Montoya, José Carlos Armario-Hita, Manuel Galán-Gutiérrez

    Published 2024-02-01
    Get full text
    Article
  7. 7
    Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group

    Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish... by Elena del Alcázar, Anna López-Ferrer, Álvaro Martínez-Doménech, Marc Julià, Ricardo Ruiz-Villaverde, Lourdes Rodríguez Fernández-Freire, Jaime Notario, Mar Llamas-Velasco, Marta Ferran, José Manuel Carrascosa

    Published 2022-08-01
    Get full text
    Article

Search Tools: